Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
INDICATION:
Patients with recurrent and/or metastatic salivary glands carcinoma who have progressed
during the 6 months period before entering the study and who are eligible for nivolumab
monotherapy.